CARDIAC Publication-derived

HERG A614V Mutation

Source Itzhaki et al. · Sohnis Research Laboratory for Cardiac Electrophysiology, Technion – Israel Institute of Technology, Haifa, Israel

👤 Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, Feldman O, Gepstein A, Arbel G, Hammerman H, Boulos M, Gepstein L ⏱ 13440 min 🧫 iPSC-Derived (Patient-Specific iPSCs — LQTS2)

Abstract

Itzhaki et al. generated patient-specific iPSC-cardiomyocytes carrying the hERG A614V mutation causing LQTS2. These cells displayed prolonged action potentials, reduced IKr current, and early afterdepolarizations. Pharmacological rescue with calcium channel blockers and K-ATP openers validated the model for therapeutic drug screening.

Cell source

iPSC-Derived (Patient-Specific iPSCs — LQTS2)

Application

LQTS2 Drug Screening

Full SOP

🔬

Create a free account to access this protocol

Join OrganMatch to unlock step-by-step procedures, reagent concentrations, QC checklists, and downloadable batch record templates.

Create free account

Already registered? Log in

Attribution

This SOP was authored by Organthis based on the published method in Itzhaki et al.. The originating laboratory holds no rights in this SOP and has not endorsed it unless marked Verified.

This wording is awaiting legal review.

Something wrong with this entry? Report an issue with this protocol

Need a commercial licence?

Use this protocol in your therapeutic or diagnostic pipeline.

Request Commercial Licence